Health literacy in the time of COVID-19In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences Share XHealth literacy in the time of COVID-19https://pharmaphorum.com/views-and-analysis/health-literacy-in-the-time-of-covid-19/
How tech-driven hubs in specialty pharmacy can improve the patient experienceThe use of specialty drugs in the U.S. has skyrocketed in recent years driven primarily by an increase Share XHow tech-driven hubs in specialty pharmacy can improve the patient experiencehttps://pharmaphorum.com/views-and-analysis/how-tech-driven-hubs-in-specialty-pharmacy-can-improve-the-patient-experience/
AZ says second COVID jab dose isn’t linked to rare clot reactionA new analysis has suggested that the rare blood clot side effects linked to AstraZeneca’s COVID-19 vaccine Vaxzevria Share XAZ says second COVID jab dose isn’t linked to rare clot reactionhttps://pharmaphorum.com/news/az-says-second-covid-jab-dose-isnt-linked-to-rare-clot-reaction/
Tackling the ‘disease of systemic racism’ in clinical trialsA lack of racial diversity in clinical trials is a long-standing, well-documented problem that contributes to the stark Share XTackling the ‘disease of systemic racism’ in clinical trialshttps://pharmaphorum.com/views-and-analysis/tackling-the-disease-of-systemic-racism-in-clinical-trials/
Rapid COVID immune status test launched in UK, IrelandYou’ve had your two COVID-19 jabs, but are you actually protected against infection? That’s a question that a Share XRapid COVID immune status test launched in UK, Irelandhttps://pharmaphorum.com/news/rapid-covid-immune-status-test-launched-in-uk-ireland/
Study finds jabs cut severe variant COVID disease after one shotA real-world study carried out in Canada has found that COVID-19 vaccines from AstraZeneca, Pfizer/BioNTech and Moderna reduce Share XStudy finds jabs cut severe variant COVID disease after one shothttps://pharmaphorum.com/news/study-finds-jabs-cut-severe-variant-covid-disease-after-one-shot/
Build back better: US pharma and the future of healthcareAmerica’s biopharmaceutical industry says it is “ready to do its part” in building a stronger, more resilient, affordable, Share XBuild back better: US pharma and the future of healthcarehttps://pharmaphorum.com/views-and-analysis/us-pharma-and-the-future-of-healthcare/
UK funds ‘long COVID’ research drive as restrictions easeThe UK government has provided almost £20 million ($27 million) in funding for 15 research projects aiming to Share XUK funds ‘long COVID’ research drive as restrictions easehttps://pharmaphorum.com/news/uk-funds-long-covid-treatment-drive-as-restrictions-ease/
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitorDuring the last two decades, the landscape for psoriasis treatment has exploded. The advent of biologic therapies at Share XThe key to psoriasis innovation? Dispelling the shadow of the JAK inhibitorhttps://pharmaphorum.com/partner-content/the-key-to-psoriasis-innovation-dispelling-the-shadow-of-the-jak-inhibitor/
